1.330USD-0.74%Mkt Cap: 4.86M USDP/E: —Last update: 2026-05-26
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap4.86M USD
Enterprise Value2.63M USD
Revenue (TTM)—
Gross Profit-38.00K USD
Net Income (TTM)-5.16M USD
Revenue/Share—
Last Price1.330 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS74584P3010
Valuation
P/E (Trailing)—
P/E (Forward)-0.30
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.89
EPS (TTM)-1.23
EPS (Forward)-4.50
52W Range
1.1602% of range9.370
52W High9.370 USD
52W Low1.160 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-135.49%
ROA-124.72%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.43M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-75.94%
Net Debt-3.32M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio4.96
Quick Ratio3.67
Book Value/Sh0.7230 USD
Cash/Share0.9100 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 6, 2019
Splits
Last Split1:20
Split DateMar 1, 2022
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.65M
Float3.65M
Insiders0.74%
Institutions9.02%
Short Interest
Short Ratio1.1d
Short % Float1.11%
Short % Out.1.11%
Shares Short40.41K
Short (prev mo.)8.05K
Technical
SMA 501.472 (-9.6%)
SMA 2003.290 (-59.6%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)27.01K
Avg Vol (10d)16.90K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—